66.2 Menopause Management & Hormone Replacement Therapy

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

66.2 Menopause Management & Hormone Replacement Therapy

Key Takeaways Explain This Topic AI

Natural menopause is diagnosed retrospectively after 12 consecutive months of amenorrhea resulting from loss of ovarian follicular activity (average age 51–52 years; normal range 45–55); diagnostic testing with FSH or estradiol is not indicated in healthy women >45 years with typical vasomotor symptoms.

The 'Timing Hypothesis' (NAMS 2022 Guidelines) establishes that systemic menopausal hormone therapy (MHT) provides a favorable benefit-risk ratio when initiated in healthy symptomatic women aged <60 years or within 10 years of menopause onset, reducing all-cause mortality, osteoporotic fractures, and coronary artery disease.

The cardinal Uterine Rule: Women with an intact uterus MUST receive systemic estrogen combined with a progestin (e.g., oral micronized progesterone 100–200 mg daily or levonorgestrel IUD) to prevent unopposed estrogen-induced endometrial hyperplasia and adenocarcinoma; women post-hysterectomy receive estrogen alone.

Transdermal estradiol bypasses hepatic first-pass metabolism, avoids stimulating hepatic synthesis of prothrombotic coagulation factors and triglycerides, and is preferred over oral estrogen in women with obesity, hypertriglyceridemia, controlled hypertension, or moderate baseline VTE risk.

Fezolinetant (Veozah 45 mg daily) is a non-hormonal neurokinin-3 (NK3) receptor antagonist that directly blocks neurokinin B hyperactivation on hypothalamic KNDy neurons to treat vasomotor symptoms; it requires baseline and periodic hepatic transaminase monitoring and is safe in women with breast cancer or thromboembolic contraindications to estrogen.

Last updated: September 2026

Clinical Staging, Definitions & Diagnostic Milestones

The menopausal transition represents a profound physiological shift characterized by the progressive depletion of ovarian follicular reserve and the cessation of cyclical ovarian steroidogenesis. Understanding the standardized clinical milestones defined by the Stages of Reproductive Aging Workshop + 10 (STRAW + 10) is critical for primary care guidance: CLINICAL MILESTONES OF FEMALE REPRODUCTIVE AGING

Stage Clinical Hallmarks Diagnostic Criteria & Hormonal Features

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Late Reproductive Stage • Regular cycles with subtle shortening of cycle • Serum FSH variable; antimüllerian
(Stage -3) length (e.g., 28 days -> 24-25 days). hormone (AMH) and antral follicle

Declining fertility. count begin progressive decline.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Early Menopause Transition • Persistent cycle length variability (difference • Widely fluctuating estradiol levels;

(Stage -2) ≥ 7 days between consecutive cycles). elevated early follicular FSH.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Late Menopause Transition • Prolonged episodes of amenorrhea (≥ 60 days). • Extreme hormonal fluctuation; frequent

(Stage -1) • Onset of prominent vasomotor symptoms vasomotor symptoms; sustained FSH > 25 IU/L.

(hot flashes, night sweats, sleep disruption).

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Natural Menopause • Complete, permanent cessation of menses. • RETROSPECTIVE CLINICAL DIAGNOSIS requiring

(Stage 0) • Average age in North America: 51.4 years 12 CONSECUTIVE MONTHS OF AMENORRHEA.

(normal physiological range: 45 to 55 years). • Routine FSH/estradiol testing NOT indicated.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
Premature Ovarian • Loss of ovarian follicular function before • Sustained hypergonadotropic hypogonadism
Insufficiency (POI) the age of 40 years. (two elevated FSH levels > 25–40 IU/L drawn

• Affects ~1% of women. ≥ 4 weeks apart) before age 40.

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════

Primary Care Diagnostic Principles

In women aged ≥ 45 \ge 45 ≥ 45 years presenting with classic irregular menses and vasomotor symptoms, routine measurement of serum FSH and estradiol is unnecessary and NOT recommended by the North American Menopause Society (NAMS / The Menopause Society) or the American College of Obstetricians and Gynecologists (ACOG). Estradiol and FSH levels fluctuate unpredictably day-to-day during perimenopause and do not alter clinical management.

When is Laboratory Testing Warranted? :

Women < 40 <40 < 40 years presenting with oligomenorrhea/amenorrhea (evaluation for Premature Ovarian Insufficiency ).

Women aged 40–45 years with atypical presentation to rule out thyroid disease (TSH), hyperprolactinemia (prolactin), and pregnancy (urine/serum hCG).

Women who have undergone hysterectomy or endometrial ablation (or have a levonorgestrel IUD in place) without bilateral oophorectomy, where absence of menses cannot be used as a marker; persistent FSH > 25 − 30 IU/L >25-30\text{ IU/L} > 25 − 30 IU/L on two occasions supports postmenopausal status.

Premature Ovarian Insufficiency (POI): Etiology & Imperative Management

POI affects approximately 1% of women under age 40. Etiologies include genetic abnormalities ( Turner syndrome mosaicism [45,X/46,XX] , Fragile X premutation [FMR1 premutation carriers] ), autoimmune destruction (associated with autoimmune polyglandular syndrome, adrenal autoantibodies, Hashimoto thyroiditis), infectious causes (mumps oophoritis), and iatrogenic gonadotoxicity (pelvic radiation, alkylating chemotherapy, bilateral salpingo-oophorectomy).

Diagnostic Workup for POI : Karyotype, FMR1 premutation testing, 21-hydroxylase adrenal autoantibodies, anti-thyroperoxidase antibodies, and baseline dual-energy X-ray absorptiometry (DEXA) scan.

Mandatory Hormone Replacement Rule : Unlike older postmenopausal women where hormone therapy is optional and tailored for symptoms, women with POI MUST be prescribed therapeutic hormone replacement therapy (systemic estrogen plus progestin) until at least the median age of natural menopause (age 51–52 years) . This is necessary to prevent premature osteoporotic hip/vertebral fractures, ischemic cardiovascular disease, and early cognitive decline.

Pathophysiology of Menopausal Manifestations
1. Vasomotor Symptoms (VMS: Hot Flashes & Night Sweats)

Vasomotor symptoms affect up to 80% of menopausal individuals, persisting for a median duration of 7.4 years (and > 10 >10 > 10 years in over 30% of women).

The Neuroendocrine Mechanism (The KNDy Neuron Discovery) : Estrogen withdrawal causes marked hypertrophy and hyperactivation of KNDy neurons (kisspeptin, neurokinin B [NKB], dynorphin) located in the arcuate nucleus of the preoptic hypothalamus.

In the hypoestrogenic state, loss of negative feedback causes excessive release of Neurokinin B (NKB) , which binds to Neurokinin-3 (NK3) receptors in the median preoptic hypothalamic thermoregulatory center.

This triggers a profound narrowing of the thermoregulatory set point zone . Consequently, minuscule, imperceptible increases in core body temperature trigger an exaggerated autonomic dissipation response: sudden peripheral vasodilatation, facial/cervical flushing, intense skin warmth, profuse diaphoresis, and compensatory shivering.

2. Genitourinary Syndrome of Menopause (GSM / Atrophic Vaginitis)

Unlike vasomotor symptoms that eventually plateau and improve over time, GSM is progressive and does NOT resolve spontaneously without active therapy .

Epithelial Pathophysiology : Estrogen is essential for maintaining the multi-layered stratified squamous epithelium of the vagina, vulva, urethra, and bladder trigone.

Circulating estradiol stimulates vaginal epithelial cell proliferation and intracellular glycogen deposition .

Normal vaginal Lactobacillus species metabolize glycogen into lactic acid, maintaining an acidic vaginal pH (3.8–4.5) that inhibits pathogenic enteric bacteria (e.g., Escherichia coli ).

Hypoestrogenic Regression : Loss of estrogen induces epithelial atrophy, thinning the mucosa to 3–4 cell layers, flattening vaginal rugae, decreasing capillary perfusion, and depleting glycogen.

Vaginal pH shifts to an alkaline range ( > 5.0 – 5.5 >5.0–5.5 > 5.0–5.5 ), leading to the loss of Lactobacillus and colonization by enteric coliforms.

Clinical Presentation : Vaginal dryness, burning, itching, dyspareunia (painful intercourse), vulvar fissures, post-coital spotting, dysuria, urinary frequency, and recurrent bacterial urinary tract infections (UTIs) .

Pelvic Exam Findings : Pale, dry, glazed mucosa with loss of rugae, petechiae, narrowing of the vaginal introitus, loss of labial fat, and introital erythema.

Menopausal Hormone Therapy (MHT / HRT)
The "Timing Hypothesis" & The Window of Opportunity (NAMS 2022 Guidelines)

Decades of clinical research following the original Women’s Health Initiative (WHI) trials have clarified that the safety and efficacy of MHT are governed entirely by the timing of therapy initiation relative to age and time elapsed since menopause : THE TIMING HYPOTHESIS FOR MENOPAUSAL HORMONE THERAPY

Parameter "Window of Opportunity" (Favorable Profile) Older / Late Initiation (High Risk)

Age & Onset Threshold • Age < 60 years, OR • Age ≥ 60 years, OR
Within 10 years of menopause onset • > 10–20 years post-menopause onset
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Cardiovascular Impact • Decreased risk of coronary artery disease (CAD) • Increased risk of acute myocardial
Reduction in all-cause mortality infarction, ischemic stroke, and
Preservation of healthy vascular endothelium destabilization of established plaques
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Bone Mineral Density • Statistically significant reduction in hip, • Fractures reduced, but cardiovascular
spine, and all non-vertebral fractures and thromboembolic risks outweigh benefit
───────────────────────────────────────────────────────────────────────────────────────────────────────────
Primary Indication • Moderate-to-severe vasomotor symptoms (VMS) • Systemic HRT should NOT be initiated
Prevention of accelerated postmenopausal bone solely for primary prevention of CAD
loss in women with osteopenia/high risk or dementia in this demographic

The Cardinal Clinical Uterine Rule

This is one of the most frequently tested concepts on the ABFM exam:

[!CRITICAL] The Uterine Protection Mandate

Women with an INTACT UTERUS : MUST receive Estrogen PLUS a Progestin (or the SERM bazedoxifene).

Unopposed systemic estrogen stimulates continuous endometrial epithelial mitogenesis without secretory transformation, leading directly to endometrial hyperplasia and endometrial adenocarcinoma (lifetime relative risk increases 4- to 8-fold).

Co-administering progestin for ≥ 12 − 14 \ge 12-14 ≥ 12 − 14 days per month (sequential regimen) or daily (continuous combined regimen) completely neutralizes this oncologic risk.

Women who have undergone HYSTERECTOMY : MUST receive Estrogen ALONE .

Progestin is completely unnecessary because there is no endometrial target tissue.

Adding a progestin post-hysterectomy needlessly exposes the patient to an increased risk of invasive breast cancer and coronary events (as shown in the WHI estrogen-plus-progestin arm, whereas the estrogen-alone arm demonstrated no increased breast cancer risk at 7 years).

Progestin Options for Endometrial Protection

Micronized Progesterone (Prometrium) : 100 mg orally once daily at bedtime (continuous) or 200 mg daily for 12 days per month (sequential). Chemically identical to endogenous human progesterone; superior cardiovascular and breast safety profile compared to synthetic progestins; produces mild sedation due to neuroactive allopregnanolone metabolites (taken at bedtime to improve sleep).

Medroxyprogesterone Acetate (MPA) : 2.5 mg daily continuous or 5–10 mg daily for 12–14 days/month. Synthetic progestin; historical standard in the WHI trial.

Levonorgestrel-Releasing Intrauterine System (LNG-IUD 52 mg) : Delivers high localized intrauterine progestin concentration to induce complete endometrial atrophy while maintaining undetectable systemic progestin levels; ideal for perimenopausal women requiring contraception and endometrial protection.

Route of Administration: Transdermal vs. Oral Estrogen COMPARISON OF ESTROGEN DELIVERY ROUTES IN MHT

Route Pharmacokinetics & Hepatic First-Pass Effect Clinical Indications & Optimal Patient Profiles

Oral 17β-Estradiol • Undergoes extensive hepatic first-pass • Inexpensive, widely accessible.

or Conjugated metabolism: • Low-risk, non-smoking, normotensive women

Equine Estrogens - Increases hepatic synthesis of clotting < 60 years of age.

(CEE) factors (prothrombin, factor VII, VIII, X). • Adverse metabolic changes: raises triglycerides,
Suppresses antithrombin III and protein S. increases C-reactive protein (CRP), increases

- Elevates hepatic SHBG (lowers free T). gallbladder disease / cholelithiasis risk.

- Increases serum triglycerides by 20–30%.

- 2- to 3-fold increased relative risk of VTE/stroke.

───────────────────────────────────────────────────────────────────────────────────────────────────────────

Transdermal • Directly absorbed into cutaneous capillary • PREFERRED FIRST-LINE ESTROGEN ROUTE for:

17β-Estradiol bed, BYPASSING HEPATIC FIRST-PASS METABOLISM: - Women with controlled hypertension
(Patch or Gel) - Zero induction of prothrombotic clotting factors. - Obesity (BMI ≥ 30 kg/m²)
Neutral effect on antithrombin III and protein S. - Hypertriglyceridemia (does not raise TG)
Does not elevate serum triglycerides or CRP. - Smokers or women with intermediate VTE risk
NO MEASURABLE INCREASE IN VENOUS THROMBOEMBOLISM - Migraine with aura / gallbladder disease risk

(DVT/PE) OR ISCHEMIC STROKE in observational data. - Avoids hepatic P450 drug interactions.

Absolute & Relative Contraindications to Systemic MHT CONTRAINDICATIONS TO SYSTEMIC MENOPAUSAL HORMONE THERAPY

Classification Clinical Condition / Comorbidity

ABSOLUTE 1. Known, suspected, or past personal history of BREAST CANCER.

CONTRAINDICATIONS 2. Known, suspected, or past history of ESTROGEN-SENSITIVE MALIGNANCY

(e.g., endometrial cancer, uterine sarcoma).

3. Active, recent, or personal history of VENOUS THROMBOEMBOLISM

(Deep Vein Thrombosis or Pulmonary Embolism).

4. Active or recent ARTERIAL THROMBOEMBOLIC DISEASE

(Acute Myocardial Infarction, Ischemic Stroke, Transient Ischemic Attack).

5. UNEXPLAINED ABNORMAL GENITAL / VAGINAL BLEEDING

(must be evaluated with transvaginal ultrasound / endometrial biopsy FIRST!).

6. ACTIVE SEVERE HEPATIC DYSFUNCTION or Acute Liver Failure.

7. Known thrombophilic disorder (Factor V Leiden homozygous, Antiphospholipid Syndrome).

8. Porphyria cutanea tarda.

───────────────────────────────────────────────────────────────────────────────────────────────────────────
RELATIVE • Controlled chronic hypertension, elevated triglycerides (> 400 mg/dL),
PRECAUTIONS severe gallbladder disease, uterine leiomyomas, severe endometriosis,

high lifetime breast cancer risk (e.g., elevated Gail model score).

Management of Isolated Genitourinary Syndrome of Menopause (GSM)

When a postmenopausal patient presents with isolated vulvovaginal atrophy, dyspareunia, or recurrent postmenopausal UTIs without bothersome systemic vasomotor hot flashes , systemic hormone replacement therapy is NOT indicated .

Low-Dose Local Vaginal Estrogen Therapy

Formulations : Micronized estradiol vaginal cream (0.5 g inserted 1–2 times weekly), vaginal estradiol tablet (10 mcg inserted twice weekly), or an estradiol-releasing silicone vaginal ring (7.5 mcg/24 hours replaced every 90 days).

Pharmacokinetics & Safety : Low-dose vaginal estrogen delivers localized cellular repair directly to the urogenital mucosa. Systemic absorption is minuscule and remains within the normal postmenopausal estradiol reference range ( < 10 – 15 pg/mL <10–15\text{ pg/mL} < 10–15 pg/mL ).

The Critical Clinical Rule : Local low-dose vaginal estrogen does NOT require concurrent progestin administration in women with an intact uterus . It does not induce endometrial proliferation. It carries no measurable risk of venous thromboembolism, stroke, or coronary disease.

Efficacy in Recurrent UTIs : Restores epithelial maturation index, normalizes acidic vaginal pH, recolonizes the introitus with protective Lactobacillus , and reduces the incidence of recurrent postmenopausal bacterial cystitis by up to 50–75%.

Non-Hormonal First-Line Options : Over-the-counter vaginal moisturizers (polycarbophil, hyaluronic acid used 2–3 times weekly) and water- or silicone-based lubricants during sexual intercourse.

Non-Hormonal Therapies for Menopausal Vasomotor Symptoms

For patients with absolute contraindications to systemic estrogens (e.g., personal history of estrogen receptor-positive breast cancer, prior pulmonary embolism) or those who choose not to take hormones, evidence-based non-hormonal pharmacotherapies are available: EVIDENCE-BASED NON-HORMONAL THERAPIES FOR VMS

Therapeutic Agent Class & Mechanism of Action Dosing & Clinical Administration Key Safety Warnings & Pearls

═══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Fezolinetant Neurokinin-3 (NK3) receptor • 45 mg PO once daily • MUST CHECK BASELINE LFTs;

(Veozah) antagonist; blocks NKB binding on with or without food repeat at 3, 6, and 9 months.

hypothalamic KNDy neurons to reset • First-in-class targeted non-hormonal • Contraindicated in severe

thermoregulatory set point zone FDA-approved therapy. cirrhosis or eGFR < 30 mL/min.

───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Paroxetine mesylate Selective Serotonin Reuptake Inhibitor • 7.5 mg PO daily at bedtime • STRICT CONTRAINDICATION IN

(Brisdelle) (SSRI); modulates central serotonin (low-dose formulation) PATIENTS ON TAMOXIFEN (potent
and adrenergic thermoregulation CYP2D6 inhibitor blocks conversion

of tamoxifen to active endoxifen!).

Venlafaxine Serotonin-Norepinephrine Reuptake • 37.5 mg to 75 mg PO once daily • Preferred in women with breast

(Effexor XR) Inhibitor (SNRI); central temperature (extended release) cancer taking tamoxifen (minimal

neuromodulation CYP2D6 inhibition). May raise BP.

Gabapentin Voltage-gated calcium channel • 300 mg PO at bedtime, titrated • Excellent choice for prominent
(Neurontin) alpha-2-delta ligand to 600–900 mg PO nightly nocturnal hot flashes and insomnia;

causes dose-dependent somnolence.

Clonidine Centrally acting alpha-2 adrenergic • 0.05 to 0.1 mg PO twice daily • Modest efficacy; limited by

(Catapres) agonist; reduces central noradrenergic or transdermal patch 0.1 mg/week dry mouth, postural hypotension,

hyperactivity and rebound hypertension.